These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32062879)

  • 21. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.
    Madden K; Kasler MK
    Semin Oncol Nurs; 2019 Oct; 35(5):150932. PubMed ID: 31561846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
    Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
    Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
    Rossi S; Castello A; Toschi L; Lopci E
    Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Non-small cell lung cancer: news from immunotherapy].
    Reinmuth N; Heigener DF; Reck M
    Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining immunotherapies to treat non-small cell lung cancer.
    Spagnuolo A; Gridelli C
    Expert Rev Respir Med; 2019 Jul; 13(7):621-634. PubMed ID: 31116072
    [No Abstract]   [Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
    Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
    Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
    Passiglia F; Commendatore O; Vitali M; Conca R
    Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 35. A banner year for immunotherapy and targeted therapy.
    Carlisle JW; Ramalingam SS
    Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
    [No Abstract]   [Full Text] [Related]  

  • 36. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
    Cyriac G; Gandhi L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
    Lim SW; Ahn MJ
    Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-based Therapies for Non-small Cell Lung Cancer.
    Rafei H; El-Bahesh E; Finianos A; Nassereddine S; Tabbara I
    Anticancer Res; 2017 Feb; 37(2):377-387. PubMed ID: 28179283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.